JP2005512016A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512016A5
JP2005512016A5 JP2002561950A JP2002561950A JP2005512016A5 JP 2005512016 A5 JP2005512016 A5 JP 2005512016A5 JP 2002561950 A JP2002561950 A JP 2002561950A JP 2002561950 A JP2002561950 A JP 2002561950A JP 2005512016 A5 JP2005512016 A5 JP 2005512016A5
Authority
JP
Japan
Prior art keywords
epitope
partial sequence
peptide
hla
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002561950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512016A (ja
Filing date
Publication date
Priority claimed from US09/935,476 external-priority patent/US20040096445A1/en
Application filed filed Critical
Publication of JP2005512016A publication Critical patent/JP2005512016A/ja
Publication of JP2005512016A5 publication Critical patent/JP2005512016A5/ja
Pending legal-status Critical Current

Links

JP2002561950A 2001-01-29 2002-01-29 A2スーパーモチーフを有するサブユニットワクチン Pending JP2005512016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26496901P 2001-01-29 2001-01-29
US09/935,476 US20040096445A1 (en) 1999-06-30 2001-08-22 Subunit vaccines with A2 supermotifs
PCT/US2002/002708 WO2002061435A2 (en) 2001-01-29 2002-01-29 Subunit vaccines with a2 supermotifs

Publications (2)

Publication Number Publication Date
JP2005512016A JP2005512016A (ja) 2005-04-28
JP2005512016A5 true JP2005512016A5 (OSRAM) 2006-01-05

Family

ID=26950859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002561950A Pending JP2005512016A (ja) 2001-01-29 2002-01-29 A2スーパーモチーフを有するサブユニットワクチン

Country Status (14)

Country Link
US (1) US20040096445A1 (OSRAM)
EP (1) EP1368659A2 (OSRAM)
JP (1) JP2005512016A (OSRAM)
KR (1) KR20040052475A (OSRAM)
CN (1) CN1653337A (OSRAM)
AU (1) AU2002243730B2 (OSRAM)
CA (1) CA2432995C (OSRAM)
CZ (1) CZ20032054A3 (OSRAM)
IL (1) IL156660A0 (OSRAM)
MX (1) MXPA03006581A (OSRAM)
NZ (1) NZ526860A (OSRAM)
RU (1) RU2003126447A (OSRAM)
SK (1) SK9512003A3 (OSRAM)
WO (1) WO2002061435A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP3548897A4 (en) * 2016-12-01 2020-08-12 Nantomics, LLC PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535024A (ja) * 1999-06-29 2003-11-25 エピミューン インコーポレイテッド Hla結合ペプチドおよびそれらの使用
CA2394741A1 (en) * 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions

Similar Documents

Publication Publication Date Title
JP2005514030A5 (OSRAM)
JP2004512815A5 (OSRAM)
WO2006076410A3 (en) Li-key/antigenic epitope hybrid peptide vaccines
EP2343318A3 (en) Antibodies binding to a C-terminal fragment of apolipoprotein E
JP2006502416A5 (OSRAM)
EP2322551A3 (en) Compositions comprising Anti-IGF-1R Antibodies and Methods for their Production
EP2287201A3 (en) RS7 antibodies
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
EP2330129A3 (en) Anti-TNF antibodies, compositions, methods and uses
JP2017501728A5 (OSRAM)
EP1741782A9 (en) Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
WO2009100376A3 (en) Modification of antigens while maintaining antibody binding epitopes
EP3056511A3 (en) Il-1beta binding antibodies and fragments thereof
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
IL273648B2 (en) Microbiota sequence variants of tumor-related antigenic epitopes
JP2005510574A5 (OSRAM)
DE60033062D1 (de) Antikörper spezifisch für dendritische zellen, zusammensetzungen und verfahren, die diese antikörper verwenden, das durch die antikörper detektierte antigen und die dadurch erhaltenen zellen
EP2287177A3 (en) Streptococcus agalactiae antigens I + II
WO2005010023A3 (en) Method for prediction of an epitope
JP2006522210A5 (OSRAM)
RU2003126447A (ru) Вакцины на основе субъединиц с супермотивами а2
WO2002008716A3 (fr) Procede de criblage de peptides utilisables en immunotherapie
JP2001516567A5 (OSRAM)
CA2542104A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2000035484A3 (en) Methods and compositions for decreasing allergic reactions to surface allergens